Research Article

The Safety and Effectiveness of Melphalan-Based Intra-Arterial Chemotherapy for Retinoblastoma: An Updated Single-Arm Systematic Review and Meta-Analysis

Table 2

MINORS appraisal scores for the included retrospective studies.

StudyMethodologic itemsTotal
123456789101112

Abramson, et al. 201622020220020214
Akyüz, et al. 201522020220020214
Chen, et al. 201722020210020213
Chen, et al. 201622020210020213
Francis, et al. 201822020210020213
Funes, et al. 201822020220020214
Ghassemi, et al. 201422020220020214
Gobin, et al. 201122020220020214
Hua, et al. 201822020220020214
Kiratli, et al. 201822020220020214
Leal-Leal, et al. 201622020220020214
Li, et al. 202122020220020214
Liu, et al. 202022020220020214
Marr, et al. 201222020220020214
Michaels, et al. 201622020220020214
Muen, et al. 201222020220020214
Munier, et al. 201122020220020214
Munier, et al. 201722020210020213
Ong, et al. 201522020210020213
Oporto, et al. 202122020220020214
Parareda, et al. 201422020220020214
Peterson, et al. 201122020220020214
Reddy, et al. 201722020220020214
Rishi, et al. 201722020210020213
Rishi, et al. 202022020210020213
Rojanaporn, et al. 201922020210020213
Shields, et al. 201422020220020214
Shields, et al. 202122020220020214
Suzuki, et al. 201122020220020214
Taich, et al. 201422020220020214
Thampi, et al. 201322020220020214
Tuncer, et al. 201622020220020214
Venturi, et al. 201322020220020214

Methodologic items: (1) a clearly stated aim; (2) inclusion of consecutive patients; (3) prospective collection of data; (4) endpoints appropriate to the aim of the study; (5) unbiased assessment of the study endpoint; (6) follow-up period appropriate to the aim of the study; (7) loss to follow-up, which is less than 5%; (8) prospective calculation of the study size; (9) an adequate control group; (10) contemporary groups; (11) baseline equivalence of groups; and (12) adequate statistical analyses. The items are scored as “0” (not reported), “1” (reported but inadequate), or “2” (reported and adequate).